Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
- Conditions
- Peripheral Arterial DiseaseCritical Limb IschemiaChronic Limb-Threatening Ischemia
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- LimFlow, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05313165
- Locations
- 🇺🇸
University of California, San Diego Health, La Jolla, California, United States
🇺🇸Stanford University School of Medicine, Palo Alto, California, United States
🇺🇸UCSF, San Francisco, California, United States
Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study
- Conditions
- Critical Limb IschemiaPeripheral Artery Disease
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- LimFlow, Inc.
- Target Recruit Count
- 192
- Registration Number
- NCT04304105
- Locations
- 🇺🇸
LA Foot & Ankle Clinic - St. Vincent's Hospital, Los Angeles, California, United States
🇺🇸Harbor- UCLA Medical Center, Torrance, California, United States
🇺🇸Denver Veterans Affairs Medical Center, Denver, Colorado, United States
PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
- Conditions
- Peripheral Artery DiseaseChronic Limb-Threatening IschemiaCritical Lower Limb IschemiaArterial OcclusionCritical Limb IschemiaArterial DiseasePeripheral Artery OcclusionPeripheral Vascular DiseaseVascular DiseasesPeripheral Arterial Disease
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- LimFlow, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03970538
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System
- Conditions
- Critical Limb IschemiaChronic Limb-Threatening Ischemia
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- LimFlow, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03124875
- Locations
- 🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Kaiser Permanente, Honolulu, Hawaii, United States
🇺🇸Metro Health, University of Michigan, Wyoming, Michigan, United States